Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial

The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is poorly understood and therapeutic strategies are lacking. This study aimed to identify plasma proteins with pathophysiological relevance in HFpEF and with respect to spironolactone-induced effects. We assessed 92 biomar...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Moritz Schnelle, Andreas Leha, Abass Eidizadeh, Katharina Fuhlrott, Tobias D. Trippel, Djawid Hashemi, Karl Toischer, Rolf Wachter, Christoph Herrmann-Lingen, Gerd Hasenfuß, Burkert Pieske, Lutz Binder, Frank Edelmann
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	MDPI AG 2021-10-01
Serie:	Cells
Ämnen:	plasma biomarkers heart failure with preserved ejection fraction spironolactone
Länkar:	https://www.mdpi.com/2073-4409/10/10/2796
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!